IL17A and psoriasis: In early studies, oral RORγt inhibitor VTP-43742 has demonstrated a reduction in Psoriasis Area and Severity Index (PASI) scores and a decrease in circulating IL-17A and IL-17F levels, indicating its potential in managing moderate to severe plaque psoriasis in patients (Table 1).